Peptide Library

Human study PLS-00184

Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.

Other design · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.primary · Pathology oncology research : POR · 2012-10-10 · PMID 23055022 · DOI

Design and participants

Design
Other design
Population
Human tissue samples: normal ovaries, primary ovarian cancers, metastatic ovarian cancers, primary stomach cancers and normal stomachs.
Conditions
ovarian cancer, stomach cancer metastatic to ovary, stomach cancer
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (per PubMed publication type); funder not named.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Tβ4 is overexpressed in primary ovarian cancers and in stomach cancers metastatic to the ovary, and it co-localizes with CD133. The authors suggest Tβ4 relates to ovarian tumorigenesis and stomach cancer metastasis and is a characteristic of stem or cancer stem cells.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Endogenous Tβ4 expression was measured in tissue; the compound was not administered to anyone.
    • abstract only: Only the abstract is available; sample numbers and methods details are not reported.
    • inappropriate endpoint: Tissue expression of endogenous protein is a surrogate and says nothing about the effect of giving the compound.
    • no control group: Cross-sectional comparison of tissue types, with no intervention or comparator group.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 23055022, abstract (sentences 7 and 10) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 23055022, abstract (sentences 3-4) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 23055022, citation (publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 23055022, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).